The Developmental Biology and Solid Tumor Program (DBSTP) brings together 30 members, including 26 Full and four Associate (junior mentored) Members from nine departments with the shared goal of improving outcomes for children and adolescents with solid tumors. In 2009, the Program underwent a change in leadership, prompted by the departure from the SJCCC of Dr. Peter Houghton (then co-leader of the Program). At that time, the SJCCC took the opportunity to reinvigorate the Program, undertaking a collaborative restructuring process that resulted in a translational research pipeline that integrates basic, translational and clinical research. The Program is now structured around three highly-integrated focus groups: (i) The Basic Research Group: This group employs developmental biology and genomic approaches to better understand the processes regulating normal development and how these processes are deregulated in childhood solid tumors. This group also includes an innovative drug discovery and drug development effort to advance molecular-targeted therapies relevant to pediatric solid tumors (ii) Translational Research Group: The translational research group provides an essential bridge between the basic and clinical research groups and is focused on the development and implementation of innovative new methods for testing therapeutics in preclinical models to guide clinical trial development. Investigators in the translational research group have expertise in pharmacokinetics and pharmacodynamics, animal models of pediatric solid tumors, and statistical design of preclinical and clinical trials, (iii) The Clinical Research Group: conducts cutting-edge clinical trials for patients with solid tumors and participates in national collaborative clinical trials through the Children's Oncology Group (COG) and other consortia. The DBSTP is supported by $6.0 million in cancer-focused grants ($4.7 million peer-reviewed, $1.3 million non-peer reviewed), and research in the program has led to 465 publications during the funding period of which 22% (n=102/465) represent intraprogrammatic collaborations, and 29% (n= 136/465) represent interprogrammatic collaborations.

Public Health Relevance

Solid tumors account for 30% of all childhood cancer deaths. Despite improvements in therapy, progress in age-adjusted mortality trends have become stagnant over the past 20 years. Outcomes for children with recurrent or metastatic solid malignancies are particularly poor. The DBSTP, together with the unique resources and collaborations available across the Cancer Center, is working to develop new therapies for these childhood cancers and reduce late effects for survivors.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Jude Children's Research Hospital
United States
Zip Code
Wu, Jianrong (2015) Power and sample size for randomized phase III survival trials under the Weibull model. J Biopharm Stat 25:16-28
Serinagaoglu, Yelda; Paré, Joshua; Giovannini, Marco et al. (2015) Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development. Dev Biol 398:97-109
Kimberg, Cara I; Klosky, James L; Zhang, Nan et al. (2015) Predictors of health care utilization in adult survivors of childhood cancer exposed to central nervous system-directed therapy. Cancer 121:774-82
Bhojwani, Deepa; McCarville, Mary B; Choi, John K et al. (2015) The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. Br J Haematol 168:845-53
Chamdine, Omar; Gaur, Aditya H; Broniscer, Alberto (2015) Effective treatment of cerebral mucormycosis associated with brain surgery. Pediatr Infect Dis J 34:542-3
Karol, Seth E; Coustan-Smith, Elaine; Cao, Xueyuan et al. (2015) Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. Br J Haematol 168:94-101
Chan, W K; Suwannasaen, D; Throm, R E et al. (2015) Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity. Leukemia 29:387-95
Gawade, Prasad L; Oeffinger, Kevin C; Sklar, Charles A et al. (2015) Lifestyle, distress, and pregnancy outcomes in the Childhood Cancer Survivor Study cohort. Am J Obstet Gynecol 212:47.e1-10
Momani, Tha'er G; Mandrell, Belinda N; Gattuso, Jami S et al. (2015) Children's perspective on health-related quality of life during active treatment for acute lymphoblastic leukemia: an advanced content analysis approach. Cancer Nurs 38:49-58
Dodd, K; Nance, S; Quezada, M et al. (2015) Tumor-derived inducible heat-shock protein 70 (HSP70) is an essential component of anti-tumor immunity. Oncogene 34:1312-22

Showing the most recent 10 out of 5513 publications